Navigation Links
Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Date:4/8/2013

ting dates are anticipated to be on or around April 25, 2013 and May 28, 2013, respectively. A management information circular containing a complete description of the Arrangement and a description of tax implications to shareholders will be sent to shareholders of Resverlogix in connection with the special meeting to approve the Arrangement.

No se podrá asegurar o garantizar que la desincorporación se lleve a cabo.

Resverlogix celebrará una rueda de prensa en directo y emisión web con preguntas y respuestas a las 11 a.m. MDT del 8 de abril de 2013.

Enlace a la emisión web:

http://services.choruscall.ca/links/resverlogix130408.html

Números de llamada de la rueda de prensa:

Canadá y Estados Unidos, número gratuito: 1-800-319-4610

Fuera de Canadá y Estados Unidos llame al número: +1-604-638-5340

Acerca de Resverlogix Corp.

Resverlogix Corp. (TSX:RVX) es una compañía cardiovascular en fase clínica con una tecnología de plataforma epigenética que modula la producción de proteína. Resverlogix está desarrollando RVX-208, una molécula pequeña de primera clase para el tratamiento de la ateroesclerosis. RVX-208 es el primer inhibidor de bromodominio BET en ensayos clínicos. Los nuevos compuestos que surgen de la plataforma de descubrimiento de fármaco epigenético de Resverlogix funcionan por medio de la inhibición de los bromodominios BET, y cuentan con el potencial para impactar en múltiples enfermedades, incluyendo el cáncer, enfermedades neurodegenerativas y diabetes mellitus. Las acciones ordinarias de Resverlogix Corp. cotizan en la Bolsa de Valores de Toronto (TSX: RVX). Si desea más información visite la página web http://www.res
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
2. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
3. Aratana Therapeutics Adds To Drug Development Team
4. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
5. Novira Therapeutics Completes $25 Million Series A Financing
6. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
7. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
8. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
9. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
10. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
11. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... BRAINTREE, Mass. , May 20, 2015  Haemonetics ... Brian Concannon , President & CEO, will present at ... New York on June 1 st , ... public may access Mr. Concannon,s presentation live via webcast ... Haemonetics Haemonetics (NYSE: HAE ) is a ...
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... North Carolina , 20. Mai ... Unternehmen für klinische Logistik (Clinical Logistics ... das Geschäftsjahr 2014, das am 31. ... Das Unternehmen hat die Marktentwicklung übertroffen ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ., (GGI) ... announce they are donating 10,010 vaccines today in recognition ... effort and commitment of clinical trial volunteers who participated ... 2014. , With a mission to advance global ... participation, GGI supports International Clinical Trials Day and how ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... , NOVATO, Calif., June 10 BioMarin Pharmaceutical Inc. (Nasdaq: ... notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as ... Canada. Priority review provides for a shortened submission review ... plans to file a marketing application for Kuvan in Canada ...
... , MINNEAPOLIS, June 10 Charles A. Dinarello, M.D., a ... Medicine in Denver and a member of the Techne Corporation ... , , On April 26, 2009, Dr. Dinarello, ... Bruce Beutler, M.D., of The Scripps Research Institute , ...
... June 10 It doesn,t take long after,you,ve polished ... are,forcefully reminded of it in the restroom. Some people ... after urinating. The unmistakable olfactory,experience is caused by organic ... of our Podcast listeners on,Chemistry in our everyday life. ...
Cached Biology Technology:Kuvan Receives Priority Review Status From Health Canada 2Kuvan Receives Priority Review Status From Health Canada 3Kuvan Receives Priority Review Status From Health Canada 4Techne Corporation Board Member Recognized 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 3
(Date:4/27/2015)... Conn. , Apr. 27, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... commence shipping to pre-order customers the first week of ... through the month of May. ... a significant milestone for the company as Wocket® enters ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 26, 2013 MedNet Solutions , a global ... systems, is pleased to announce that Accelovance , ... early phase Oncology, Vaccines and General Medicine development, has ... Program .    Designation as an iMedNet Partner ...
... citrus greening, looms darkly over the United States, threatening ... fruit alone was valued at more than $3.4 billion ... by a University of California, Davis, plant scientist used ... how citrus greening impacts trees before they even show ...
... than $25 million over four years will help three ... of genomic variants relevant to human disease and the ... practice. The awards are from the National Institutes of ... sequencing the DNA of whole genomes (the body,s entire ...
Cached Biology News:MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 3New study offers hope for halting incurable citrus disease 2New study offers hope for halting incurable citrus disease 3New NIH-funded resource focuses on use of genomic variants in medical care 2New NIH-funded resource focuses on use of genomic variants in medical care 3
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Ultra-sensitive, non-radioactive detection of rat Big Endothelin-1 (Big ET-1)...
Qa-1 (L-12)...
Request Info...
Biology Products: